Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
Key Highlights
- ➤ATNM-400 first cohort cleared 1.0 µCi/kg without dose-limiting toxicities
- ➤ATNM-400 dose escalation advanced to 1.5 µCi/kg in mCRPC
- ➤RADIANZ first patient dosed across five advanced solid-tumor types
- ➤Cash and equivalents totaled $28.7 million, expected to fund operations through 2027
- ➤Actinium formed Scientific Advisory Board and appointed two senior leaders
Expert Statements
Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals
“With ATNM-400 now in the clinic, we are advancing a differentiated HER3-targeted approach to alpha radiotherapy with the potential to address significant unmet needs in prostate cancer beyond PSMA.”
Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals
“Our encouraging initial clinical findings support continued dose escalation in mCRPC, while RADIANZ represents an important next step in evaluating HER3 targeting across multiple large solid tumor indications.”
Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals
“Looking ahead, 2027 is shaping up to be an important year for Actinium, with anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT.”
Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals
“Together with our newly formed Scientific Advisory Board and strengthened leadership team, we believe we are well positioned to execute on these priorities and build value across our differentiated targeted radiotherapy pipeline.”
Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress PR Newswire
* Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026 * Initiated RADIANZ pan-tumor imaging study to inform ATNM-400 development across multiple solid tumors beyond prostate cancer * Formed Scientific Advisory Board and strengthened leadership team to support strategic execution, business development and continued pipeline advancement * KOL webinar on ATNM-400 on December 1, 2026, at 8:00 a.m. ET with Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline. With ATNM-400 now in clinical development for prostate cancer and multiple clinical and scientific milestones anticipated across its portfolio in 2027, Actinium is entering an important period of pipeline advancement.
Get started
Create a free account to read the full story.
